Flag­ship launch­es Sen­da Bio­sciences with $88M in back­ing, look­ing to pi­o­neer the field of 'In­ter­sys­tems Bi­ol­o­gy'

Flag­ship Pi­o­neer­ing has a fresh com­pa­ny out this week, one that aims to lay the ground­work for a whole new dis­ci­pline.

Sen­da Bio­sciences launched Wednes­day with $88 mil­lion in Flag­ship cash. The goal? Gain in­sights in­to the mol­e­c­u­lar con­nec­tions be­tween peo­ple and co­e­volved non­hu­man species like plants and bac­te­ria, paving the way for “In­ter­sys­tems Bi­ol­o­gy.”

Guil­laume Pfe­fer has been tapped to run the show, a 25-year biotech vet­er­an who comes from GSK af­ter lead­ing the de­vel­op­ment of the com­pa­ny’s shin­gles vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER